A multicenter, double-blind, randomized, parallel-group, placebo controlled, 7 cycle duration of oral SH T00658ID [estradiol valerate/dienogest] for the treatment of dysfunctional uterine bleeding.

Trial Profile

A multicenter, double-blind, randomized, parallel-group, placebo controlled, 7 cycle duration of oral SH T00658ID [estradiol valerate/dienogest] for the treatment of dysfunctional uterine bleeding.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Estradiol valerate/dienogest (Primary)
  • Indications Menorrhagia
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 10 Jan 2012 Results of a pooled analysis (CTPs 13663 and 16199) published in Contraception.
    • 01 Oct 2011 Results published in Human Reproduction.
    • 09 Oct 2008 Checked against the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top